Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – EurekAlert
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
IMAGE: Tina Cascone, M.D., Ph.D.
view more
Credit: MD Anderson Cancer Center
HOUSTON — The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas…
-
Noosa News20 hours agoTwo trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business21 hours agoUp 105% in a year, are Pro Medicus shares still a good buy today?
-
Noosa News16 hours agoQueensland man sentenced to four years imprisonment after string of terror offences
-
Business19 hours agoEverything you need to know about the Coles dividend